DrugPatentWatch Database Preview
Drugs in Development Information for GDC-0152
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for GDC-0152?
GDC-0152 is an investigational drug.
There have been 165 clinical trials for GDC-0152.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Leukemia. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
There are seven US patents protecting this investigational drug and one hundred and nineteen international patents.
Summary for GDC-0152
| US Patents | 7 |
| International Patents | 119 |
| US Patent Applications | 16 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2010-07-01) |
| Vendors | 21 |
Recent Clinical Trials for GDC-0152
| Title | Sponsor | Phase |
|---|---|---|
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Horm | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer Spread to the Bones | National Cancer Institute (NCI) | Phase 2 |
| A Study Evaluating the Efficacy and Safety of GDC-0077 + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer | Hoffmann-La Roche | Phase 2/Phase 3 |
Clinical Trial Summary for GDC-0152
Top disease conditions for GDC-0152
Top clinical trial sponsors for GDC-0152
US Patents for GDC-0152
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GDC-0152 | Start Trial | Inhibitors of IAP | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| GDC-0152 | Start Trial | Inhibitors of IAP | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| GDC-0152 | Start Trial | Inhibitors of IAP | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| GDC-0152 | Start Trial | Inhibitors of IAP | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| GDC-0152 | Start Trial | Inhibitors of IAP | GENENTECH, INC. (South San Francisco, CA) | Start Trial |
| GDC-0152 | Start Trial | Biomarkers for IAP inhibitor therapy | Novartis AG (Basel, CH) | Start Trial |
| GDC-0152 | Start Trial | Inhibitors of IAP | GENENTECH, INC. (South San Franscisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GDC-0152
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GDC-0152 | Australia | 2005270104 | 2024-07-02 | Start Trial |
| GDC-0152 | Australia | 2009243421 | 2024-07-02 | Start Trial |
| GDC-0152 | Australia | 2011236020 | 2024-07-02 | Start Trial |
| GDC-0152 | Australia | 2012241077 | 2024-07-02 | Start Trial |
| GDC-0152 | Brazil | PI0511350 | 2024-07-02 | Start Trial |
| GDC-0152 | Canada | 2570321 | 2024-07-02 | Start Trial |
| GDC-0152 | China | 101035802 | 2024-07-02 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
